First Episode Psychosis Clinical Trial
Official title:
VIP (Vitamins In Psychosis) Study. A Randomized Double Blind Placebo Controlled Trial of the Effects of Vitamin B12, B6 and Folic Acid Augmentation on Cognition and Symptoms in Early Psychosis.
The purpose of this study is to determine whether Vitamin B12,B6 and Folic Acid are effective with antipsychotic medication in the treatment of First Episode Psychosis.The B-complex Vitamins' homocysteine lowering properties may have an effect on cognition and symptoms. We are examining changes in symptoms and cognition over a 3 month period.
The core rationale of this study will be to prospectively investigate whether Vitamin B12,
B6 and Folic Acid and the associated lowering of homocysteine levels will improve and /or
protect cognitive functioning in a cohort of 120 first episode psychosis patients.
This is a randomized, double blind placebo controlled add on standard therapy trial with
vitamin B12, B6 and folic acid, in young patients between 15-25 presenting to ORYGEN Youth
Health with a first psychotic episode . Vitamins (B12 , B6 and Folate) will be compared with
placebo added to standard treatment for a period of 12 weeks in a double blind fashion.
Primary outcome measures will be psychopathology and cognition (CogState and MATRICS).
Secondary outcome measures will be tolerability and safety measures (drop-out rates, general
side effect scale (UKU).
Patients who give informed consent will be randomised to receive treatment with vitamin (5
mg folic acid, 0.4 mg B12, and 50 mg B6) daily or placebo for 12 weeks.
Patients will be randomised by a dynamic randomisation method called minimization which
allocates patients to treatment group by checking the allocation of similar patients already
randomised, and allocating the next treatment group "live" to best balance the treatment
groups across all stratification variables. The minimization will be carried out by the
NHMRC clinical trials centre in Sydney , and the patient will be randomized to either
placebo or vitamin. Each patient will collect their tablets from the clinical trials
pharmacy. The Clinical Trials Pharmacy will dispense either vitamin or placebo. All study
personnel and participants will be blinded to treatment assignment for the duration of the
study. To enhance the quality of measurement (and increase the power of the study by
avoiding dilution of effect) adherence to medication will be measured electronically with
electronic pill caps (Medication Event Monitoring System VI, ARRDEX Ltd). This will allow us
to assess actual pharmacological exposure in an objective manner.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Completed |
NCT01026584 -
Efficacy and Safety of Aripiprazole in First Episode Psychosis
|
Phase 4 | |
Completed |
NCT03983421 -
Feasibility of an Early Detection Program for Early Psychosis on a College Campus
|
||
Recruiting |
NCT04046497 -
Artificial Intelligence to Measure Adherence to Oral Medication
|
Phase 4 | |
Withdrawn |
NCT04369677 -
Thermoregulation Among Individuals With First-episode Psychosis
|
||
Completed |
NCT03568500 -
A Trial to Explore Acceptance and Performance of Using a Digital Medicine System With Healthcare Professionals and Adults With Schizophrenia, Schizoaffective Disorder, or First Episode Psychosis on an Oral Atypical Antipsychotic
|
Phase 4 | |
Completed |
NCT03102151 -
Reducing the Duration of Untreated Psychosis
|
||
Completed |
NCT00916461 -
Role of Minocycline in First Episode Psychosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT05310838 -
Optimizing Engagement in Services for First-Episode Psychosis
|
N/A | |
Completed |
NCT03501160 -
Socially Inappropriate Behaviour in People With First Episode Psychosis: A Caregivers' Perspective
|
||
Recruiting |
NCT03196128 -
Early Intervention Psychosis Communication and Engagement Trial
|
N/A | |
Recruiting |
NCT04005378 -
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs
|
Phase 4 | |
Recruiting |
NCT03919760 -
Early Psychosis Intervention - Spreading Evidence-based Treatment
|
||
Completed |
NCT03409393 -
Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis
|
N/A | |
Completed |
NCT01753284 -
First Episode Psychosis and Pathway to Care in Nordland
|
||
Completed |
NCT01157585 -
Efficacy and Safety of Paliperidone ER in First Episode Psychosis
|
Phase 4 | |
Completed |
NCT05737966 -
Evaluation of Case Management for First Episode Psychosis Using the PEPsy-CM Checklist
|
||
Recruiting |
NCT04021719 -
OnTrackNY's Learning Healthcare System
|
||
Recruiting |
NCT04889911 -
Pilot RCT of Self-stigma Treatment for First Episode Psychosis
|
N/A | |
Recruiting |
NCT04853485 -
Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity Biotypes
|
N/A |